Investors

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Volition's research and development activities are centered in Belgium, with an innovation hub in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

Stock Snapshot

IR Contacts

Company

VolitionRx Ltd
1489 West Warm Springs Road
Ste 110
Henderson , NV 89014
US
T: +1-646-650-1351
info@volition.com

Investor Relations

VolitionRx
T: +1-646-650-1351
investorrelations@volition.com

Edison Advisors
Soo Romanoff
T: +1 (773) 573 9779
sromanoff@edisongroup.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: +1-212-828-8436
F: +1-646-536-3179
info@vstocktransfer.com
https://www.vstocktransfer.com

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.